Nycomed resolute on pursuing damages from Teva, Sun over generic Protonix
This article was originally published in Scrip
Swiss firm Nycomed, which has been hit by at-risk launches of generic versions of Protonix (pantoprazole) by Teva Pharmaceutical Industries and Sun Pharma in the US, appears determined to pursue damage claims against the two firms, leaving little hope for the possibility of a settlement with them prior to the expiry of the Protonix patent next year.
You may also be interested in...
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.